Holdings A/S Novo - Jun 12, 2023 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role
10%+ Owner
Signature
/s/ Barbara Fiorini Due, General Counsel, Finance & Operations of Novo Holdings A/S
Stock symbol
CYT
Transactions as of
Jun 12, 2023
Transactions value $
-$13,423
Form type
4
Date filed
6/14/2023, 08:18 PM
Previous filing
Feb 21, 2023
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Sale -$1.86K -900 -0.02% $2.06 3.94M Jun 12, 2023 Direct F1
transaction CYT Common Stock Sale -$5.51K -2.63K -0.07% $2.10 3.94M Jun 13, 2023 Direct F2
transaction CYT Common Stock Sale -$6.05K -2.87K -0.07% $2.11 3.93M Jun 14, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.